Latest market price
93.47
-1.01-1.07%
News
Down 1.1% — CVS Pharmacy expands fall assortment of collectibles, nostalgic favorites and seasonal exclusives (prnewswire.com).
Medium confidence
TA
Loading chart...
Snapshot
| Index | S&P 500 | P/E | 24.73 | EPS (ttm) | 3.78 | Insider Own | 1.35% | Shs Outstand | 1.28B | Perf Week | 1.20% |
| Market Cap | 119.55B | Forward P/E | 10.97 | EPS next Y | 8.52 | Insider Trans | -22.04% | Shs Float | 1.28B | Perf Month | 9.90% |
| Enterprise Value | 179.98B | PEG | 2.49 | EPS next Q | - | Inst Own | 89.13% | Short Float | 1.29% | Perf Quarter | -12.70% |
| Income | 4.91B | P/S | 0.29 | EPS this Y | 20.71% | Inst Trans | 0.00% | Short Ratio | 2.15 | Perf Half Y | 19.93% |
| Sales | 415.09B | P/B | 1.50 | EPS next Y | 5.86% | ROA | 1.93% | Short Interest | 16.47M | Perf YTD | 17.78% |
| Book/sh | 62.47 | P/C | 8.56 | EPS next 5Y | 9.92% | ROE | 6.43% | 52W High | 110.68 -15.55% | Perf Year | 13.97% |
| Cash/sh | 10.91 | P/FCF | 10.17 | EPS past 3/5Y | -24.73% -23.94% | ROIC | 4.09% | 52W Low | 69.51 34.47% | Perf 3Y | 31.48% |
| Dividend Est. | 2.66 (2.85%) | EV/EBITDA | 13.42 | Sales past 3/5Y | 7.63% 8.39% | Gross Margin | 14.15% | Volatility | 1.88% 2.40% | Perf 5Y | 8.89% |
| Dividend TTM | 2.66 (2.85%) | EV/Sales | 0.43 | EPS Y/Y TTM | 3.28% | Oper. Margin | 2.00% | ATR (14) | 2.16 | Perf 10Y | 6.22% |
| Dividend Ex-Date | Oct 22, 2026 | Quick Ratio | 0.66 | Sales Y/Y TTM | 11.34% | Profit Margin | 1.18% | RSI (14) | 57.88 | Recom | 2.10 |
| Dividend Gr. 3/5Y | 6.53% 5.87% | Current Ratio | 0.87 | EPS Q/Q | 42.54% | SMA20 | 4.61% | Beta | 0.56 | Target Price | 111.25 |
| Payout | 69.63% | Debt/Eq | 1.24 | Sales Q/Q | 7.26% | SMA50 | 2.03% | Rel Volume | 0.57 | Prev Close | 94.48 |
| Employees | 259,500 | LT Debt/Eq | 1.16 | Earnings | Nov 04 | SMA200 | 5.59% | Avg Volume | 8.03M | Price | 93.47 |
| IPO Date | Feb 21, 1973 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 39.14% 6.07% | Net Debt/EBITDA | 4.85 | Volume | 4,600,376 | Change | -1.07% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-12-26 | Reiterated | Leerink Partners | Outperform | $98 → $112 |
| Sep-09-26 | Reiterated | Bernstein | Outperform | $106 → $112 |
| Sep-09-26 | Reiterated | BMO Capital | Market Perform | $120 → $112 |
| Sep-09-26 | Reiterated | Piper Sandler | Overweight | $113 → $112 |
| Sep-03-26 | Reiterated | UBS | Buy | $126 → $118 |
| Aug-19-26 | Reiterated | Argus Research | Buy | $90 → $114 |
| Aug-06-26 | Reiterated | Robert W. Baird | $94 → $107 | |
| Aug-06-26 | Reiterated | UBS | Buy | $122 → $126 |
| Aug-06-26 | Reiterated | Barclays | Overweight | $106 → $108 |
| Jul-24-26 | Reiterated | UBS | Buy | $97 → $122 |
Latest News· Times ET
Oct-23-26
09:00AM
Oct-22-26
Oct-22-2604:31AM
02:41AM
Oct-21-26
Oct-20-26
09:00AM
Oct-19-26
Oct-19-2609:14AM
04:26AM
Oct-16-26
Oct-15-26
09:00AM
Oct-14-26
10:32AM
Company
CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.
Ownership
Total institutional ownership89.13%
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 415,086 | 402,067 | 372,809 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 356,340 | 346,705 | 321,408 | — | — | — | — | — | — | |
| Gross Profit | 58,746 | 55,362 | 51,401 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 0 | 0 | 41,229 | — | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | — | — | — | — | — | — | |
| Other Operating Expense | 50,458 | 44,977 | 1,656 | — | — | — | — | — | — | |
| Operating Income | 8,288 | 10,385 | 8,516 | — | — | — | — | — | — | |
| Interest Expense | 3,102 | 3,119 | 2,958 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 601 | -5,130 | 590 | — | — | — | — | — | — | |
| Net Income Before Taxes | 5,787 | 2,136 | 6,148 | — | — | — | — | — | — | |
| Income Taxes | 916 | 408 | 1,562 | — | — | — | — | — | — | |
| Consolidated Net Income | 4,906 | 1,768 | 4,614 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 4,871 | 1,728 | 4,586 | — | — | — | — | — | — | |
| Net Income | 4,906 | 1,768 | 4,614 | — | — | — | — | — | — | |
| EPS (Recurring) | 3.83 | 1.40 | 3.66 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 3.83 | 1.40 | 3.66 | — | — | — | — | — | — | |
| EPS (Diluted) | 3.78 | 1.39 | 3.66 | — | — | — | — | — | — | |
| EBITDA | 13,411 | 9,861 | 13,683 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 24.73 | 57.09 | 12.27 | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.29 | 0.25 | 0.15 | — | — | — | — | — | — | |
| Gross Margin | 14.15 | 13.77 | 13.79 | — | — | — | — | — | — | |
| Operating Margin | 2.00 | 2.58 | 2.28 | — | — | — | — | — | — | |
| Net Margin | 1.18 | 0.44 | 1.24 | — | — | — | — | — | — | |
| Shares Outstanding | 1,276 | 1,267 | 1,259 | — | — | — | — | — | — | |
| Market Capitalization | 119,268 | 100,549 | 56,517 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| ROBBINS LARRY | Director | May 21 '26 | Sale | 75.69 | 748,462 | 56,652,627 | 0 | May 21 |
| ROBBINS LARRY | Director | May 20 '26 | Sale | 93.82 | 1,018,000 | 95,510,822 | 5,195,261 | May 21 |
| ROBBINS LARRY | Director | May 19 '26 | Sale | 94.45 | 1,983,538 | 187,341,307 | 6,213,261 | May 21 |
| Mandadi Tilak | EVP, Chief Exp & Tech Officer | May 08 '26 | Sale | 89.58 | 69,551 | 6,230,379 | 10,133 | May 11 |
| Nelson Steven H | EVP and President, Aetna | Jan 23 '25 | Buy | 53.70 | 24 | 1,289 | 24 | Jan 27 |
| CAPOZZI HEIDI B | EVP and Chief People Officer | Oct 23 '24 | Buy | 56.85 | 35 | 1,990 | 85 | Oct 14 |
| CAPOZZI HEIDI B | EVP and Chief People Officer | Oct 02 '24 | Buy | 62.24 | 10 | 622 | 50 | Oct 14 |
| CAPOZZI HEIDI B | EVP and Chief People Officer | Sep 09 '24 | Buy | 56.47 | 35 | 1,976 | 40 | Oct 14 |
| Finucane Anne A. | Director | Aug 20 '25 | Sale | 71.02 | 7,500 | 532,650 | 22,156 | Aug 29 |
| SANSONE GUY P | Director | Jun 05 '25 | Buy | 63.70 | 1,570 | 100,009 | 12,007 | Jun 09 |
| ROBBINS LARRY | Director | May 06 '25 | Sale | 66.67 | 150,000 | 10,000,710 | 8,196,799 | May 06 |
| ROBBINS LARRY | Director | May 05 '25 | Sale | 67.41 | 1,323,932 | 89,249,945 | 8,346,799 | May 06 |
| ROBBINS LARRY | Director | May 02 '25 | Sale | 67.86 | 2,276,068 | 154,444,758 | 9,670,731 | May 06 |
| Shah Prem S | EVP and Group President | Mar 17 '25 | Option Exercise | 62.21 | 846 | 52,630 | 43,190 | Mar 18 |
| Clark James David | SVP, Cont & Chief Acct Officer | Mar 05 '25 | Option Exercise | 62.21 | 7,513 | 467,384 | 15,907 | Mar 07 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.